David L. Cutler

5.1k total citations
145 papers, 3.9k citations indexed

About

David L. Cutler is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, David L. Cutler has authored 145 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 25 papers in Molecular Biology and 23 papers in Epidemiology. Recurrent topics in David L. Cutler's work include Cancer Treatment and Pharmacology (21 papers), Diabetes Treatment and Management (11 papers) and Antiplatelet Therapy and Cardiovascular Diseases (10 papers). David L. Cutler is often cited by papers focused on Cancer Treatment and Pharmacology (21 papers), Diabetes Treatment and Management (11 papers) and Antiplatelet Therapy and Cardiovascular Diseases (10 papers). David L. Cutler collaborates with scholars based in United States, Argentina and United Kingdom. David L. Cutler's co-authors include Paul Statkevich, Teddy Kosoglou, Melton B. Affrime, Larisa Reyderman, Pascale Reidenberg, Eric K. Rowinsky, Margaret Dugan, Elaine Radwanski, Dasja Pajkrt and Tom van der Poll and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David L. Cutler

145 papers receiving 3.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David L. Cutler United States	31	938	888	737	627	544	145	3.9k
Irene Helenowski United States	39	898 1.0×	1.7k 1.9×	683 0.9×	470 0.7×	967 1.8×	232	5.7k
Emma D. Deeks New Zealand	41	1.4k 1.5×	1.1k 1.2×	540 0.7×	265 0.4×	474 0.9×	156	5.0k
Grant W. Cannon United States	41	592 0.6×	658 0.7×	568 0.8×	599 1.0×	699 1.3×	200	6.2k
Lin Zhou China	34	973 1.0×	948 1.1×	470 0.6×	198 0.3×	959 1.8×	261	4.5k
Lionel D. Lewis United States	36	1.4k 1.5×	1.7k 1.9×	252 0.3×	425 0.7×	806 1.5×	167	4.2k
Eun Bong Lee South Korea	39	980 1.0×	1.1k 1.2×	959 1.3×	784 1.3×	496 0.9×	242	7.2k
Ardeshir Ghavamzadeh Iran	36	2.3k 2.4×	1.0k 1.2×	492 0.7×	2.0k 3.1×	502 0.9×	363	6.5k
Kathleen M. Egan United States	49	1.6k 1.7×	2.8k 3.1×	645 0.9×	387 0.6×	1.0k 1.9×	159	7.8k
M. H. van Rijswijk Netherlands	37	1.1k 1.1×	520 0.6×	359 0.5×	655 1.0×	281 0.5×	64	6.9k
Kate McKeage New Zealand	37	913 1.0×	644 0.7×	419 0.6×	158 0.3×	383 0.7×	125	4.1k

Countries citing papers authored by David L. Cutler

Since Specialization

Citations

This map shows the geographic impact of David L. Cutler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Cutler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Cutler more than expected).

Fields of papers citing papers by David L. Cutler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Cutler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Cutler. The network helps show where David L. Cutler may publish in the future.

Co-authorship network of co-authors of David L. Cutler

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Cutler. A scholar is included among the top collaborators of David L. Cutler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Cutler. David L. Cutler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hong, Jin‐Bon, Po‐Yuan Wu, Albert Qin, et al.. (2022). Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results. Pharmaceutics. 14(10). 2159–2159. 4 indexed citations

Rugo, Hope S., Francisco Barrios, Suyapa Bejarano, et al.. (2022). Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology. 41(1). 65–74. 12 indexed citations

Cutler, David L., et al.. (2022). Contact Sensitization and Phototoxic and Photoallergic Potential of Tirbanibulin 1% Ointment in Healthy Volunteers. SHILAP Revista de lepidopterología. 3(2). 100170–100170. 2 indexed citations

Jackson, Christopher, Eva Segelov, Hans Prenen, et al.. (2021). Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study. British Journal of Clinical Pharmacology. 87(12). 4670–4680. 11 indexed citations

Blauvelt, Andrew, Steven Kempers, Susana Puig, et al.. (2020). LB918 Tirbanibulin, a novel inhibitor of tubulin polymerisation and src kinase signaling, for actinic keratosis (AK): Results of two phase-3 studies and 1-year follow-up data. Journal of Investigative Dermatology. 140(7). B3–B3. 1 indexed citations

Smolinski, Michael, Yahao Bu, James L. Clements, et al.. (2018). Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). Journal of Medicinal Chemistry. 61(11). 4704–4719. 72 indexed citations

Sahasrabudhe, Vaishali, Steven G. Terra, Anne Hickman, et al.. (2018). Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment. Clinical Therapeutics. 40(10). 1701–1710. 19 indexed citations

Kosoglou, Teddy, Paul Statkevich, Bhavna Kantesaria, et al.. (2014). Vorapaxar, an oral PAR‐1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone. Clinical Pharmacology in Drug Development. 4(1). 56–62. 2 indexed citations

Tortorici, Michael A., David L. Cutler, Lei Zhang, & Marc Pfister. (2012). Design, Conduct, Analysis, and Interpretation of Clinical Studies in Patients With Impaired Kidney Function. The Journal of Clinical Pharmacology. 52(S1). 109S–18S. 11 indexed citations

10.

Kosoglou, Teddy, Larisa Reyderman, Renger G. Tiessen, et al.. (2011). Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. European Journal of Clinical Pharmacology. 68(3). 249–258. 76 indexed citations

11.

Wong, Nan Soon, Kellen L. Meadows, Lee S. Rosen, et al.. (2011). A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer. Cancer Investigation. 29(9). 617–625. 10 indexed citations

12.

Kosoglou, Teddy, et al.. (2010). Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. European Journal of Clinical Pharmacology. 67(5). 483–492. 10 indexed citations

13.

Reyderman, Larisa, Teddy Kosoglou, David L. Cutler, Stephen E. Maxwell, & Paul Statkevich. (2005). The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. Current Medical Research and Opinion. 21(8). 1171–1179. 14 indexed citations

14.

Kosoglou, Teddy, Paul Statkevich, Bo Yang, et al.. (2004). Pharmacodynamic interaction between ezetimibe and rosuvastatin. Current Medical Research and Opinion. 20(8). 1185–1195. 49 indexed citations

15.

Tolcher, Anthony W., Stanton L. Gerson, Denis Lairon, et al.. (2003). Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. British Journal of Cancer. 88(7). 1004–1011. 285 indexed citations

16.

Kosoglou, Teddy, Ingo Meyer, Enrico P. Veltri, et al.. (2002). Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. British Journal of Clinical Pharmacology. 54(3). 309–319. 91 indexed citations

17.

Keung, Anther, Teddy Kosoglou, Paul Statkevich, et al.. (2001). Ezetimibe does not affect the pharmacokinetics of oral contraceptives. Clinical Pharmacology & Therapeutics. 69(2). 55. 27 indexed citations

18.

Adjei, Alex A., Charles Erlichman, J. Nathan Davis, et al.. (2000). A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.. PubMed. 60(7). 1871–7. 201 indexed citations

19.

Nomeir, Amin A., Elaine Radwanski, David L. Cutler, et al.. (1997). Single‐Dose Pharmacokinetics of Isepamicin in Young and Geriatric Volunteers. The Journal of Clinical Pharmacology. 37(11). 1021–1030. 3 indexed citations

20.

Cutler, David L.. (1986). Community residential options for the chronically mentally ill. Community Mental Health Journal. 22(1). 61–73. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact